CHRISTOPHER FABIAN: Open Payments
NPI 1649328923 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$584 in 42 payments from 7 companies in 2025. Trend: 2023 $115 · 2024 $91 · 2025 $584
Food & beverage: $584
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $277 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $66 |
| Alkermes, Inc. | 3 | $54 |
| Neurocrine BioSciences, Inc. | 3 | $54 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Braeburn Inc. | 2 | $32 |
Products named: VRAYLAR, REXULTI, CAPLYTA, ARISTADA, INGREZZA, COBENFY, BRIXADI.
Industry payments across NY — which companies pay providers there.
